📇 Rhumatologue · NANCY · (54) · Salarié

MME NORA BOUCHERAB-BRIK

Pourquoi vous devez consulter ce praticien

2 raisons identifiées

Auteur de référence en rhumatologie
30 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
146.3 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 NANCY (54)SalariéRPPS 10100698421

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

FAM PIERRE VIVIER ( ARS )
SITE PIERRE VIVIER 156 BD D'AUSTRASIE, 54000 NANCY
☎ 0383304300Activité de soin et de pharmacie

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Clinical features of retinal vasculitis: A systematic review and meta-analysis from the International Uveitis Study Group (IUSG) Retinal Vasculitis Study (ReViSe) Report 3

Survey of ophthalmology · 2025

📚 5 citations🎯 RCR 2.63🔓 Open Access

Global demographic and etiological variations of retinal vasculitis: A systematic review and meta-analysis: International Uveitis Study Group (IUSG) Retinal Vasculitis Study (ReViSe) Report 1

Survey of ophthalmology · 2025

📚 5 citations🎯 RCR 2.65🔓 Open Access

SGLT2-is in Acute Heart Failure

Journal of clinical medicine · 2025

📚 3 citations🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Despite the wealth of evidence in favour of SGLT2 inhibitor use in patients with chronic heart failure, their role in the very early stages of heart failure is still unclear. While the latest update of the European Society of Cardiology guidelines on heart failure advocates the use SGLT2 inhibitors in the acute phases of heart failure based on the results of the latest trials, it does not clarify the appropriate timing to start this therapy, leaving the clinician to decide whether SGLT2 inhibitors should be started directly during hospitalization or at discharge. Conversely, the recently published focused update of the American College of Cardiology expert consensus decision pathway on the clinical assessment, management, and trajectory of patients hospitalized with heart failure clearly supports the safety and early clinical benefit use of SGLT2 inhibitors based on evidence coming from the EMPULSE and SOLOIST-WHF trials. The expert consensus decision pathway states that SGLT2 inhibitors can be initiated regardless of left ventricular ejection fraction at any time during hospitalization and places a greater emphasis on implementing the other pillars of therapy for heart failure with reduced ejection fraction after stabilization. Moreover, the results of the very recent DAPA ACT HF–TIMI 68 trial on dapagliflozin in patients with acute heart failure, although limited by a follow-up of only 2 months, did not show a reduction in mortality or heart failure hospitalizations. Based on the currently available published data, we will review what is already known about the use of these drugs in the early phases of acute heart failure and analyze their pathophysiological rationale from a practical perspective.

Cookies & analyse de trafic

MME NORA BOUCHERAB-BRIK

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (30) — classées par pathologie

Transversal9

Revue générale8

Revue / méta-analyse5

Case report / série3

Épidémiologie & registres2

Essai clinique2

Lupus2

Recommandations2

Ostéoporose1

Pédiatrie1

Vascularites des gros vaisseaux1

Vraie vie / RWE1

Partager cette fiche